Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Metric	ABBVAbbVie	AMGNAmgen	GILDGilead Sciences
Snapshot
Price	$265.16	$409.05	$153.15
Market cap	$461.26B	$201.93B	$162.98B
Valuation
P/E	127.8x	28.5x	20.5x
Forward P/E	147.7x	21.7x	14.6x
Growth
Revenue growth	9.5%	9.1%	3.5%
EPS growth	-13.5%	31.3%	55.5%
Profitability
Net margin	5.8%	21.0%	31.0%
ROE	95.6%	89.4%	42.2%
Balance sheet & cash
Debt / equity	20.19x	6.31x	1.1x
Free cash flow yield	3.9%	6.0%	5.2%
Dividend yield	3.1%	2.9%	2.6%
Verdict
Investment rating	Weak· 31	Favorable· 62	Strong· 74

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

Year	ABBVtoday $265	AMGNtoday $409	GILDtoday $153
2027	$202.85 – $297.51+12% CAGR	$402.72 – $590.66+44% CAGR	$178.60 – $261.95+71% CAGR
2028	$206.90 – $303.46+7% CAGR	$528.65 – $775.35+38% CAGR	$277.70 – $407.30+63% CAGR
2029	$211.04 – $309.53+5% CAGR	$693.96 – $1,017.81+36% CAGR	$431.80 – $633.31+61% CAGR
2030	$215.26 – $315.72+4% CAGR	$910.96 – $1,336.08+34% CAGR	$671.41 – $984.74+59% CAGR
2031	$219.57 – $322.03+4% CAGR	$1,195.82 – $1,753.87+34% CAGR	$1,043.98 – $1,531.17+58% CAGR
5-yr CAGR	-3.7% – 4.0%	23.9% – 33.8%	46.8% – 58.5%